Jenburkt Pharmaceuticals Ltd vs Supriya Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Jenburkt Pharmaceuticals Ltd is ₹ 1042 as of 04 May 15:30 . The P/E Ratio of Jenburkt Pharmaceuticals Ltd changed from 11.1 on March 2021 to 13.9 on March 2025 . This represents a CAGR of 4.60% over 5 yearsThe P/E Ratio of Supriya Lifescience Ltd changed from 26.1 on March 2022 to 31.4 on March 2025 . This represents a CAGR of 4.73% over 4 years The Market Cap of Jenburkt Pharmaceuticals Ltd changed from ₹ 182.84 crore on March 2021 to ₹ 446.49 crore on March 2025 . This represents a CAGR of 19.55% over 5 yearsThe Market Cap of Supriya Lifescience Ltd changed from ₹ 3967 crore on March 2022 to ₹ 5903 crore on March 2025 . This represents a CAGR of 10.45% over 4 years The revenue of Jenburkt Pharmaceuticals Ltd for the Dec '25 is ₹ 44.84 crore as compare to the Sep '25 revenue of ₹ 47.64 crore. This represent the decline of -5.88% The revenue of Supriya Lifescience Ltd for the Dec '25 is ₹ 209.05 crore as compare to the Sep '25 revenue of ₹ 202.56 crore. This represent the growth of 3.2% The ebitda of Jenburkt Pharmaceuticals Ltd for the Dec '25 is ₹ 9.24 crore as compare to the Sep '25 ebitda of ₹ 15.18 crore. This represent the decline of -39.13% The ebitda of Supriya Lifescience Ltd for the Dec '25 is ₹ 74.24 crore as compare to the Sep '25 ebitda of ₹ 75.37 crore. This represent the decline of -1.5% The net profit of Jenburkt Pharmaceuticals Ltd changed from ₹ 7.42 crore to ₹ 5.93 crore over 7 quarters. This represents a CAGR of -12.02% The net profit of Supriya Lifescience Ltd changed from ₹ 44.64 crore to ₹ 49.68 crore over 7 quarters. This represents a CAGR of 6.30% The Dividend Payout of Jenburkt Pharmaceuticals Ltd changed from 28.37 % on March 2021 to 24.76 % on March 2025 . This represents a CAGR of -2.69% over 5 yearsThe Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 4.28 % on March 2025 . This represents a CAGR of 5.99% over 5 years .

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Limited, incorporated in 1985, was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family.
The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe.
The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements.

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

FAQs for the comparison of Jenburkt Pharmaceuticals Ltd and Supriya Lifescience Ltd

Which company has a larger market capitalization, Jenburkt Pharmaceuticals Ltd or Supriya Lifescience Ltd?

Market cap of Jenburkt Pharmaceuticals Ltd is 459 Cr while Market cap of Supriya Lifescience Ltd is 5,571 Cr

What are the key factors driving the stock performance of Jenburkt Pharmaceuticals Ltd and Supriya Lifescience Ltd?

The stock performance of Jenburkt Pharmaceuticals Ltd and Supriya Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jenburkt Pharmaceuticals Ltd and Supriya Lifescience Ltd?

As of May 5, 2026, the Jenburkt Pharmaceuticals Ltd stock price is INR ₹1042.2. On the other hand, Supriya Lifescience Ltd stock price is INR ₹692.2.

How do dividend payouts of Jenburkt Pharmaceuticals Ltd and Supriya Lifescience Ltd compare?

To compare the dividend payouts of Jenburkt Pharmaceuticals Ltd and Supriya Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.